Page 77 - Программа - Всероссийский конгресс с международным участием «Нейронауки: интеграция теории и практики», 18-19 ноября 2022 года, Онлайн

Russian Military Medical
SCIENTIFIC REVIEWS Vol. 41 (4) 2022 Academy Reports
426

16. Chauhan N., Maekawa T., Kumar D.N.S. Graphene based biosen- 22. Sainz-Urruela C., Vera-López S., San Andrés M.P., Díez-Pascual
sors-Accelerating medical diagnostics to new-dimensions // J. Mater. A.M. Graphene-Based Sensors for the Detection of Bioactive Com-
Res. 2017. Vol. 32, No. 15. P. 2860–2882. DOI: 10.1557/jmr.2017.91 pounds: A Review // Int. J. Mol. Sci. 2021. Vol. 22, No. 7. P. 3316.
17. Li M., Yang X., Ren J., et al. Using graphene oxide high near-infrared DOI: 10.3390/ijms22073316
absorbance for photothermal treatment of Alzheimer’s disease // Adv. 23. Rembach A., Faux N.G., Watt A.D., et al. Changes in plasma amyloid
Mater. 2012. Vol. 24, No. 13. P. 1722–1728. DOI: 10.1002/adma.201104864 beta in a longitudinal study of aging and Alzheimer’s disease // Alzheim-
18. Demeritte T., Nellore B.P., Kanchanapally R., et al. Hybrid Gra- ers Dement. 2014. Vol. 10. P. 53–61. DOI: 10.1016/j.jalz.2012.12.006
phene Oxide Based Plasmonic-Magnetic Multifunctional Nanoplat- 24. Davies D.R., Sheriff S., Padlan E.A. Antibody-Antigen Complex-
form for Selective Separation and Label-Free Identification of Al- es // J. Biological Chemistry. 1988. Vol. 263, No. 22. P. 10541–10544.
zheimer’s Disease Biomarkers // ACS Appl. Mater. Interfaces. 2015. DOI: 10.1146/annurev.biochem.59.1.439
Vol. 7, No. 24. P. 13693–13700. DOI: 10.1021/acsami.5b03619 25. Усиков A.С., Лебедев С.П., Роенков А.Д., и др. Исследование
19. Chae M.S., Kim J., Jeong D., et al. Enhancing surface functional- чувствительной способности графена для применений в каче-
ity of reduced graphene oxide biosensors by oxygen plasma treat- стве биосенсоров // Письма в журнал технической физики. 2020.
ment for Alzheimer’s disease diagnosis // Biosens Bioelectron. 2017. Т. 46, № 10. С. 3–6.
Vol. 92. P. 610–617. DOI: 10.1016/j.bios.2016.10.049 26. Sun L., Zhong Y., Gui J., et al. A hydrogel biosensor for high se-
20. Leszek J., Md Ashraf G., Tse W.H., et al. Nanotechnology for lective and sensitive detection of amyloid-beta oligomers // Int. J.
Alzheimer Disease // Curr. Alzheimer Res. 2017. Vol. 14, No. 11. Nanomedicine. 2018. Vol. 13. P. 843–856. DOI: 10.2147/IJN.S152163
P. 1182–1189. DOI: 10.2174/1567205014666170203125008 27. Toyos-Rodríguez C., García-Alonso F.J., de la Escosura-Muñiz A.
21. Speranza G. Carbon Nanomaterials: Synthesis, Functionalization Electrochemical Biosensors Based on Nanomaterials for Early De-
and Sensing Applications // Nanomaterials (Basel). 2021. Vol. 11, tection of Alzheimer’s Disease // Sensors (Basel). 2020. Vol. 20,
No. 4. P. 967. DOI: 10.3390/nano11040967 No. 17. P. 4748. DOI: 10.3390/s20174748

REFERENCES
1. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Specificity and Potential for Clinical Use. J Pers Med. 2020;10(3):116.
Nat Rev Neurol. 2011;7(3):137–152. DOI: 10.1038/nrneurol.2011.2 DOI: 10.3390/jpm10030116
2. Tahami Monfared AA, Byrnes MJ, White LA, Zhang Q. Alzheim- 10. Harada R, Okamura N, Furumoto S, et al. Characteristics of
er’s Disease: Epidemiology and Clinical Progression. Neurol Ther. Tau and Its Ligands in PET Imaging. Biomolecules. 2016;6(1):7.
2022;11(2):553–569. DOI: 10.1007/s40120-022-00338-8 DOI: 10.3390/biom6010007
3. Elonheimo HM, Andersen HR, Katsonouri A, Tolonen H. Envi- 11. Camus V, Payoux P, Barré L, et al. Using PET with 18F-AV-45 (flor-
betapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl
ronmental Substances Associated with Alzheimer’s Disease-A
Scoping Review. Int J Environ Res Public Health. 2021;18(22):11839. Med Mol Imaging. 2012;39(4):621–631. DOI: 10.1007/s00259-011-2021-8
12. Mielke MM, Hagen CE, Wennberg AMV, et al. Association of
DOI: 10.3390/ijerph182211839 plasma total tau level with cognitive decline and risk of mild cogni-
4. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of
tive impairment or dementia in the mayo clinic study on aging. JAMA
dementia due to Alzheimer’s disease: recommendations from the
Neurol. 2017;74:1073–1080. DOI: 10.1001/jamaneurol.2017.1359
National Institute on Aging–Alzheimer’s Association workgroups 13. Hanon O, Vidal JS, Lehmann S, et al. Plasma amyloid levels within
on diagnostic guidelines for Alzheimer’s disease. Alzheim dement. the Alzheimer’s process and correlations with central biomarkers. Al-
2011;7(3):263–269. DOI: 10.1016/j.jalz.2011.03.005 zheimers Dement. 2018;14:858–868. DOI: 10.1016/j.jalz.2018.01.004
5. Jack CR, Albert MS, Knopman DS, et al. Introduction to the rec- 14. Jia L, Qiu Q, Zhang H, et al. Concordance between the assess-
ommendations from the National Institute on Aging–Alzheimer’s As- ment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-
sociation workgroups on diagnostic guidelines for Alzheimer’s disease. derived exosomes and cerebrospinal fluid. Alzheimers Dement.
Alzheim dement. 2011;7(3):257–262. DOI: 10.1016/j.jalz.2011.03.004 2019;15:1071–1080. DOI: 10.1016/j.jalz.2019.05.002
6. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the 15. Lebedev AA, Davydov VYu, Novikov SN, et al. Graphene-based
preclinical stages of Alzheimer’s disease: recommendations from biosensors. Technical Physics Letters. 2016;42(14):28–35. (In Russ.)
DOI: journals.ioffe.ru/articles/viewPDF/43411
the National Institute on Aging–Alzheimer’s Association workgroups
16. Chauhan N, Maekawa T, Kumar DNS. Graphene based biosen-
on diagnostic guidelines for Alzheimer’s disease. Alzheim dement.
sors-Accelerating medical diagnostics to new-dimensions. J Mater
2011;7(3):280–292. DOI: 10.1016/j.jalz.2011.03.003
Res. 2017;32(15):2860–2882. DOI: 10.1557/jmr.2017.91
7. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild
17. Li M, Yang X, Ren J, et al. Using graphene oxide high near-infra-
cognitive impairment due to Alzheimer’s disease: recommendations
red absorbance for photothermal treatment of Alzheimer’s disease.
from the National Institute on Aging-Alzheimer’s Association work-
Adv Mater. 2012;24(13):1722–1728. DOI: 10.1002/adma.201104864
groups on diagnostic guidelines for Alzheimer’s disease. Alzheim 18. Demeritte T, Nellore BP, Kanchanapally R, et al. Hybrid Graphene
Dement. 2011;7(3):270–279. DOI: 10.1016/j.jalz.2011.03.008 Oxide Based Plasmonic-Magnetic Multifunctional Nanoplatform
8. Emelin AYu, Lobzin VYu, Vorob’ev SV. Cognitive disorders: for Selective Separation and Label-Free Identification of Alzheim-
a guide for doctors. Moscow: T8 Izdatel’skiуe Tekhnologii Publishing er’s Disease Biomarkers. ACS Appl Mater Interfaces. 2015;7(24):
House; 2019. 416 p. (In Russ.) 13693–13700. DOI: 10.1021/acsami.5b03619
9. d’Abramo C, D’Adamio L, Giliberto L. Significance of Blood and 19. Chae MS, Kim J, Jeong D, et al. Enhancing surface functionality
Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Sensitivity, of reduced graphene oxide biosensors by oxygen plasma treatment
DOI: https://doi.org/10.17816/rmmar111884